Don’t get confused with all the various prostate cancer terms and drugs. The following resources can help you with these. You can also find these links in the Resources section of this website.
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on
Highlights and summary from the 24th Annual PCF Scientific Retreat on October 2017. Read the report here.
US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
- Presented by: Bayer
- Sponsored by: Dendreon and Jannsen Oncology
- In Kind Sponsor: Los Padres
- Guest Speakers:
- Dr. Edwin Morales – Urology Specialist, San Antonio
- Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
- Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
- Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
Watch the recording here
Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.
- Robert Sinha, MD, Medical Director of Radiation Oncology
- Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
- Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
- Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
- Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute
View the recording of the event here
A Short Course in Prostate Cancer – eBook
The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.
The information and opinions provided in this book are not specific medical advice for any individual. It should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.
Download the pdf ebook here.
Fabio Almeida, MD // Phoenix Molecular Imaging – Phoenix Insight Imaging/CDI
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to be contributing to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published. This represents the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview PET/CT imaging for Prostate Cancer follow for your review. We hope you find this information useful.
Read or download the report from here
Dr. Thomas Hope, Assistant Professor of Radiology at UCSF presented at the San Jose Prostate Cancer Support Group on the topic of Prostate-specific membrane antigen (PSMA) imaging and treatment of patients with prostate cancer.
Read or download his presentation from here
Article by Fabio D Almeida1, Chi-Kwan Yen1, Mark C Scholz2, Richard Y Lam2, Jeffrey Turner2, Larry L Bans3, Robert Lipson3
Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.
Read or download the report from here
Following a prostate cancer diagnosis, patients are faced with a multitude of care options, the advisability of which is influenced by patient factors and by cancer severity or aggressiveness. The ability to categorize patients based on cancer aggressiveness is invaluable for facilitating care decisions.
Accordingly, these guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options.
In Scope: active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy.
Out of Scope: Secondary or salvage treatment for localized prostate cancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease.